Arkolith/Insider Trading/AVTX/Form 4

Doyle Mittie

Chief Medical OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Mar 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$412K
Net Open-Market Flow
-$412K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 16, 2026Option exercise(M)20K$12.65$247K23K
Mar 16, 2026Option exercise(M)6K$8.04$48K29K
Mar 16, 2026Sell(S)25K$16.15$412K4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 16, 2026Option exercise(M)20K—$0215K
Mar 16, 2026Option exercise(M)6K—$0149K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001918845-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML